Corcept Faces Securities Class Action Over Relacorilant Disclosures as Firms Rally Investors Before April 21 Deadline

Overview

• Multiple shareholder firms, including Hagens Berman, Robbins LLP, DJS Law Group and The Schall Law Firm, are inviting Corcept investors to seek lead‑plaintiff status by April 21, 2026.
• The filed complaint alleges violations of Sections 10(b) and 20(a) and Rule 10b‑5 based on statements that relacorilant was “approaching approval” and backed by “powerful” trial evidence.
• Corcept disclosed on December 31, 2025 that the FDA issued a Complete Response Letter requiring additional evidence of effectiveness, prompting a roughly 50% one‑day share decline to $34.80.
• An updated FDA letter on January 30, 2026 said the agency had repeatedly warned Corcept in pre‑submission meetings that its clinical program was inadequate and that significant review issues were expected.
• The putative class covers investors who bought Corcept shares from October 31, 2024 through December 30, 2025, and a case captioned Allegheny County Employees’ Retirement System v. Corcept Therapeutics Inc. is pending in the Northern District of California.